Serious adverse events (including mortality) · adults and children with chronic asthma
Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).
1 finding from 1 review
Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Serious or severe adverse events N of participants with positive severe adverse events · people with acne scars
It is very uncertain whether chemical peeling changes serious or severe adverse events N of participants with positive… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Serious adverse events at 1 week to 1 year Assessed via self‐report and medical records · People who smoke cigarettes
Nicotine EC showed no clear difference in serious adverse events at 1 week to 1 year Assessed via self‐report… compared with non‐nicotine EC (low certainty).
1 finding from 1 review
Serious adverse events at 4 weeks to 1 year Assessed via self‐report and medical records · people who smoke
Nicotine EC showed no clear difference in serious adverse events at 4 weeks to 1 year Assessed via self‐report… compared with NRT (low certainty).
1 finding from 1 review
Participants with adverse events ‐ serious adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ serious adverse eventsClinical or… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious local adverse events (low risk of bias) inactivated HAV… (high certainty).
1 finding from 1 review
Serious adverse events – measured by self‐report and medical records · people who smoke
It is very uncertain whether nicotine EC changes serious adverse events at 4 weeks to 8 months Assessed via… compared with behavioural support only/no support (very low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Total number of serious adverse events (infection, thrombosis, other serious adverse events · patients with knee replacement surgery
Preoperative education showed no clear difference in total number of serious adverse events (infection, thrombosis, other… compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious systemic adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The intervention showed no clear difference in non‐serious systemic adverse events (low risk of bias) inactivated… (high certainty).
1 finding from 1 review
Serious adverse events among subjects in the adverse event substudy clinical manifestations · people at risk for postherpetic neuralgia
Vaccination leads to higher serious adverse events among subjects in the adverse event substudy… compared with placebo (high certainty).
1 finding from 1 review
Risk of serious adverse events, including those that may be complications of the common cold · adults and children with colds and/or upper respiratory infections
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause non‐fatal serious adverse events ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/mometasone… compared with salmeterol/ICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of participants who experienced operative or postoperative serious adverse events · patients with multiple sclerosis and chronic cerebrospinal venous insufficiency (CCSVI)
The intervention showed no clear difference in proportion of participants who experienced operative or… (moderate certainty).
1 finding from 1 review
Total number of serious adverse events (infection, thrombosis, other serious adverse events · hip replacement
It is very uncertain whether preoperative education changes total number of serious adverse events (infection, thrombosis, other… compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 · patients with preventing hepatitis A.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone… compared with salmeterol/ICS (low certainty).
1 finding from 1 review